13 Aug 2012, BioSpectrum Bureau , BioSpectrum
New Delhi: Ranbaxy Laboratories has reported a 55 percent growth in sales revenue in the second quarter of 2012 over the corresponding quarter in 2011. Consolidated sales for the company stood at $588 million ( Rs. 31,741 million) against $459 million (Rs 20,537 million) for the same quarter last year.
Commenting on the business results for the quarter, Mr Arun Sawhney, CEO & MD, Ranbaxy, said, "Sales and profitability grew in the quarter with overall improvement across major regions, aided further by exclusivity sales in some of the key markets. We capitalized on our product focus approach with the successful monetization of the Atorvastatin and Atorvastatin + Amlodipine opportunities. The launch Synriam, the first new drug from India, was one of the high points of the quarter. The strategy to build long term, differentiated value drivers was rewarded with two NDA approvals in the dermatological space in the USA."